Maya Mann, PA
Internal Medicine · Ewing, NJNPI 1295167807
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,892 of the $6,792 with a category attached, or 86.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$724
- AbbVie$506
- Lilly USA, LLC$405
- Sanofi-aventis U.S. LLC$368
- plus $2K from 20 others
What the payments were for
- Consulting fees$80012%
- Travel & lodging$1001%
- Food & beverage$5,89287%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,592 |
| Biohaven Pharmaceuticals, Inc. | 11 | $1,166 |
| Novo Nordisk | 53 | $724 |
| AbbVie(2 entities) | 33 | $506 |
| Lilly USA, LLC | 19 | $405 |
| Sanofi-aventis U.S. LLC | 25 | $368 |
| Exact Sciences | 21 | $366 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $245 |
| GSK | 14 | $209 |
| Axsome Therapeutics, Inc. | 7 | $200 |
| Pfizer | 12 | $186 |
| Abbott | 9 | $167 |
| Boehringer Ingelheim | 8 | $125 |
| Bayer | 5 | $84 |
| Merck | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $69 |
| Dexcom, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Boston Scientific | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| VBI Vaccine (delaware) Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,792 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $126,775 |
| RybelsusSemaglutide | 51 | $75,782 |
| FarxigaDapagliflozin Propanediol | 75 | $64,273 |
| TrulicityDulaglutide | 22 | $41,360 |
| MounjaroTirzepatide | 17 | $34,363 |
| EliquisApixaban | 33 | $34,009 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $27,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $22,411 |
| ViberziEluxadoline | 13 | $20,178 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $19,472 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $18,799 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $13,640 |
| MyrbetriqMirabegron | 16 | $12,894 |
| JardianceEmpagliflozin | 14 | $12,349 |
| JanuviaSitagliptin Phosphate | 13 | $11,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $724 | $202,557128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $405 | $75,72339 claims |
| AstraZenecaFarxiga | $1,592 | $64,27375 claims |
| Boehringer IngelheimSynjardy Xr, Combivent Respimat, Jardiance | $125 | $44,78855 claims |
| PfizerEliquis | $186 | $34,00933 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $209 | $26,81928 claims |
| AbbVieViberzi | $506 | $20,17813 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $368 | $19,47212 claims |
| MerckJanuvia, Janumet | $74 | $19,08629 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $18 | $10,98315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Ewing
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.